| Glaucoma, Open-Angle
Alphagan P vs Rocklatan
Side-by-side clinical, coverage, and cost comparison for glaucoma, open-angle.Deep comparison between: Alphagan P vs Rocklatan with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRocklatan has a higher rate of injection site reactions vs Alphagan P based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rocklatan but not Alphagan P, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Alphagan P
Rocklatan
At A Glance
Ophthalmic
Three times daily
Alpha-2 adrenergic receptor agonist
Ophthalmic
Once daily (evening)
Rho kinase inhibitor / prostaglandin F2alpha analogue
Indications
- Glaucoma, Open-Angle
- Ocular Hypertension
- Glaucoma, Open-Angle
- Ocular Hypertension
Dosing
Glaucoma, Open-Angle, Ocular Hypertension One drop in the affected eye(s) three times daily, approximately 8 hours apart; if used with other topical ophthalmic products, instill at least 5 minutes apart.
Glaucoma, Open-Angle, Ocular Hypertension One drop in the affected eye(s) once daily in the evening; do not exceed once daily. If used with other topical ophthalmic drugs, administer at least 5 minutes apart.
Contraindications
- Neonates and infants (pediatric patients younger than 2 years old)
- Previous hypersensitivity reaction to any component of ALPHAGAN P
—
Adverse Reactions
Most common (>=10%) Allergic conjunctivitis, conjunctival hyperemia, eye pruritus
Serious Potentiation of vascular insufficiency, severe cardiovascular disease
Postmarketing Bradycardia, depression, hypersensitivity, iritis, keratoconjunctivitis sicca, miosis, nausea, skin reactions, syncope, tachycardia
Most common (>=11%) Conjunctival hyperemia, instillation site pain, corneal verticillata, conjunctival hemorrhage
Postmarketing Epithelial corneal edema in patients with pre-existing corneal stromal edema or ocular procedures affecting corneal endothelial function
Pharmacology
Brimonidine tartrate is a relatively selective alpha-2 adrenergic receptor agonist that lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow, with a peak ocular hypotensive effect at approximately 2 hours post-dosing.
Fixed-dose combination of netarsudil (Rho kinase inhibitor) and latanoprost (prostaglandin F2alpha analogue) that reduces elevated intraocular pressure by increasing the outflow of aqueous humor.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Alphagan P
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Rocklatan
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (6/12) · Qty limit (9/12)
UnitedHealthcare
Alphagan P
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Rocklatan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (2/8) · Qty limit (4/8)
Humana
Alphagan P
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (0/3)
Rocklatan
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Alphagan P.
No savings programs available for Rocklatan.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Alphagan PView full Alphagan P profile
RocklatanView full Rocklatan profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.